Organigram (US:OGI) ZACKS·2025-12-16 14:46分组1 - OrganiGram reported a quarterly loss of $0.20 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -1,900% [1] - The company generated revenues of $56.91 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.1%, and showing a year-over-year increase from $32.77 million [2] - OrganiGram has not surpassed consensus EPS estimates in the last four quarters, but has topped revenue estimates three times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - OrganiGram shares have increased by approximately 11.8% since the beginning of the year, compared to a 15.9% gain for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $51.11 million, with a breakeven forecast on revenues of $213.92 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 30% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The estimate revisions trend for OrganiGram was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]